Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.9741
- Book/Share 2.5079
- PB 18.8129
- Debt/Equity 1.856
- CurrentRatio 4.9795
- ROIC 0.1086
- MktCap 10268349560.0
- FreeCF/Share 0.5326
- PFCF 85.9233
- PE 54.6786
- Debt/Assets 0.5562
- DivYield 0
- ROE 0.3817
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HIMS | Needham | Buy | Hold | -- | -- | June 23, 2025 |
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
HIMS Stock Crashes 30% in a Day: Time to Buy the Dip?
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health ( HIMS ) has been one of the market's standout growth stocks in recent years. The company has successfully built a direct-to-consumer health platform targeting conditions like hair loss, mental health, and more recently, weight loss—delivering very strong revenue growth and stock returns.
Read More
Weight Loss Woes: Hims & Hers (HIMS) Shares Under Pressure
Published: June 23, 2025 by: Schwab Network
Sentiment: Negative
Hims & Hers (HIMS) shares are reeling after Novo Nordisk (NVO) severs its weight-loss drug relationship with the telehealth company. NVO claims HIMS was marketing knock-off weight loss drugs using "deceptive promotion" tactics.
Read More
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON HIMS & HERS HEALTH, INC. (HIMS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On June 23, 2025, Novo Nordisk announced that it was.
Read More
NYSE: HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors with Significant Losses to Contact the Firm
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Hims & Hers Health, Inc. (NYSE: HIMS) (“Hims & Hers”). On June 23, 2025, during pre-market hours, the pharmaceutical company Novo Nordisk announced it would no longer provide Hims & Hers with direct access to its FDA-approved weight loss drug Wegovy through NovoCare Pharmacy due to.
Read More
US strikes Iran nuclear sites, Tesla shares rise, Hims & Hers falls
Published: June 23, 2025 by: Yahoo Finance
Sentiment: Neutral
Here are some of the stories covered on Market Catalysts for Monday, June 23. Stocks wavered on news that the US bombed Iranian nuclear sites.
Read More
Novo Nordisk Ends Partnership with Hims & Hers
Published: June 23, 2025 by: WSJ
Sentiment: Negative
The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations about Hims' compounding and deceptive marketing practices.
Read More
Rosen Law Firm Encourages Hims & Hers Health, Inc. Investors to Inquire About Securities Class Action Investigation – HIMS
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Hims & Hers Health, Inc. (NYSE: HIMS) resulting from allegations that Hims & Hers may have issued materially misleading business information to the investing public. So What: If you purchased Hims & Hers securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conti.
Read More
Top Stock Movers Now: Tesla, Hims & Hers, Wolfspeed, and More
Published: June 23, 2025 by: Investopedia
Sentiment: Neutral
U.S. equities advanced at midday as oil prices declined on doubts the weekend U.S. military strikes against Iran and possible retaliation from Iran would disrupt supplies. The Dow Jones Industrial Average, S&P 500, and Nasdaq all gained.
Read More
Hims & Hers shares drop after Novo Nordisk ends Wegovy collaboration over compounding practices
Published: June 23, 2025 by: Proactive Investors
Sentiment: Negative
Shares of Hims & Hers Health (NYSE:HIMS) fell around 30% on Monday after Novo Nordisk (NYSE:NVO) terminated its collaboration with the telehealth company, citing violations related to compounding and marketing of the weight-loss drug Wegovy. Novo said it ended Hims & Hers' access to the FDA-approved treatment through its NovoCare platform, alleging that the company engaged in illegal mass compounding and deceptive marketing.
Read More
Novo Nordisk under pressure, ends deal with Hims & Hers
Published: June 23, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details on the pharmaceutical space.
Read More
Novo Nordisk, Hims and Hers Shares Tumble on Severed Ties
Published: June 23, 2025 by: Schaeffers Research
Sentiment: Negative
Novo Nordisk A/S (NYSE:NVO) stock is down 5.3% to trade at $69.90 at last check, after the drugmaker's obesity drug CagriSema showed no clear advantage over Eli Lilly's (LLY) Zepbound.
Read More
BREAKING: Hims & Hers Health, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Hims & Hers Health, Inc. (NYSE: HIMS) for potential securities law violations. Investors who have lost money in their Hims & Hers Health, Inc. investment should contact the firm to learn more about how they might recover those losses.
Read More
HIMS Plummets, AMD Upgrade, DASH 3-Year High
Published: June 23, 2025 by: Schwab Network
Sentiment: Negative
Diane King Hall joins Nicole Petallides at the NYSE to focus on several early movers in Monday's trading session. Hims & Hers (HIMS) shares drop on news that Novo Nordisk (NVO) will no longer allow the telehealth company to sell its weight loss drug Wegovy.
Read More
Hims & Hers' stock plunges. Here's why Wegovy parent ended its partnership with the company.
Published: June 23, 2025 by: Market Watch
Sentiment: Negative
Hims & Hers Health Inc.'s stock fell sharply on Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth-consultation company less than two months after it started.
Read More
Hims & Hers stock crashes over 20% on Wegovy shocker
Published: June 23, 2025 by: Finbold
Sentiment: Negative
Hims & Hers Health (NYSE: HIMS) stock has plunged sharply after Novo Nordisk (NYSE: NVO) announced it was severing ties with the telehealth firm over concerns about the distribution of its weight loss drug, Wegovy.
Read More
Hims & Hers Stock Plunges as Novo Nordisk Abruptly Ends Partnership
Published: June 23, 2025 by: Barrons
Sentiment: Negative
Novo Nordisk accuses the telehealth company of breaking a law related to drug compounding.
Read More
Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
Published: June 23, 2025 by: CNBC
Sentiment: Negative
Novo Nordisk said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company's sales and promotion of cheaper knock-offs of the weight loss drug Wegovy. Novo Nordisk in April said it would offer Wegovy through several telehealth companies, such as Hims & Hers, to expand access to the blockbuster injection now that it is no longer in short supply in the U.S.
Read More
Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral
Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy ® that put patient safety at risk Novo Nordisk won't stop taking action to protect Americans from the dangers of illicit foreign active pharmaceutical ingredients in knock-off drugs Efforts will continue to make authentic, FDA-approved Wegovy® directly available through NovoCare ® Pharmacy to select telehealth organizations that share our commitment to safe and effective medical treatment for patients living with chronic diseases PLAINSBORO, N.J. , June 23, 2025 /PRNewswire/ -- Novo Nordisk announced today that the company will …
Read More
Novo Nordisk ends collaboration with Hims & Hers over weight loss drug sale
Published: June 23, 2025 by: Reuters
Sentiment: Negative
Novo Nordisk said on Monday it would halt its collaboration with Hims & Hers Health over the sale of weight loss drugs.
Read More
3 Stocks to 3X in 3 Years
Published: June 22, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Key Points in This Article: Long-term investing over three to five years — or ideally decades — leverages compounding returns to build wealth, outperforming short-term trading's volatility and frequent losses.
Read More
Why The Hims & Hers Health Rally Has Room To Run
Published: June 20, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers reported 2.4 million subscribers in Q1 FY25, a 38% YoY increase from 1.74 million in Q1 FY24. Personalized treatments now make up 58% of the subscriber base, with 70% of new users choosing customized care in Q1. Monthly online revenue per subscriber rose 50% YoY to $84, driven by high adoption of tailored daily treatments.
Read More
Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
HIMS accelerates global growth with ZAVA deal, AI investments and expanded access to obesity care treatments. However, macro challenges may hurt performance.
Read More
Hims & Hers: Outsized Subscription Growth Is Enviable - Premium Valuations
Published: June 19, 2025 by: Seeking Alpha
Sentiment: Positive
The bulls have well defended Hims & Hers' recovery from the April 2025 bottom (near to our fair value estimates), thanks to the growing adoption of its personalized healthcare offerings. These have directly triggered the growing subscriber base/ Revenue per Average Subscriber, with the improved manufacturing/ operating scale contributing to the richer profit margins. This is significantly aided by the growing GLP-1 partnership and the regulatory exemption surrounding compounding personalization, lending support to the raised FY2025 guidance and ambitious 2030 targets.
Read More
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
Read More
2 Reasons To Double Down On Hims & Hers Ahead Of August
Published: June 16, 2025 by: Seeking Alpha
Sentiment: Positive
I expected Hims & Hers' stock to break $50, and now I'm buckling up for another rally, with EMAs stacked bullishly at the moment. The company's partnership with Novo Nordisk and the ZAVA acquisition for European expansion should drive the next leg of growth. Wegovy sales and potential cheaper Ozempic offerings are set to boost revenue, with subscriber growth and ARPU at record highs despite macro headwinds.
Read More
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
These 24 Stocks Are Ripe for a Short Squeeze
Published: June 12, 2025 by: Schaeffers Research
Sentiment: Neutral
With the way negative stock market sentiment has piled up recently, short squeezes have generated some massive returns.
Read More
HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth
Published: June 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
Hims & Hers' 38.4% subscriber growth and $576.4 million online revenues highlight the power of its personalized subscription model.
Read More
Bought $40,000 of Hims & Hers (HIMS) Stock on a YOLO – Is it Time to Sell?
Published: June 10, 2025 by: 24/7 Wall Street
Sentiment: Positive
Hims & Hers is an exciting stock in the telehealth sector, but as a growth stock, it's not for the faint of heart.
Read More
Why Hims & Hers Health (HIMS) Might be Well Poised for a Surge
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Andrew Dudum
- Employees 1637